Francesca Deflorian

This inventor holds 13 USPTO granted patents and 1 published patent application, plus 1 CIPO patent and 6 EPO patents, primarily in CGRP Antagonist Compounds. Top assignees: Heptares Therapeutics Limited, Nxera Pharma UK Limited. Active years: 2017-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Francesca Deflorian. Retrieved from https://idiyas.com/inventor/francesca-deflorian

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 13 (Patent Applications = 1)

% Patents Active = 100.0

CIPO Patents = 1 (Patent Applications = 6)

EPO Patents = 6 (Patent Applications = 8)

Average Co-Inventor Count = 6.5

ph-index = 4

Forward Citations = 26(Granted Patents)

Location History:

Welwyn Garden City, GB (2017 - 2019)
Welwyn Garden, GB (2017 - 2019)
Cambridge, GB (2019 - 2021)

Company Filing History:

8 out of 85

Heptares Therapeutics Limited

patents

5 out of 18

Nxera Pharma UK Limited

patents

Years Active: 2017-2026

Loading Chart...

Areas of Expertise:

CGRP Antagonists

Triazolone Compounds

Cancer Treatment

Pharmaceuticals

Receptor Antagonists

Pyrimidine Compounds

Biochemical Research

Therapeutics

13 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12552799 - Triazolone compounds (2026-02-17),

2. 12528815 - 5-amino-8-(4-pyridyl)-[1,2,4]triazolo[4,3-c]pyrimidin-3-one compounds for use against cancer (2026-01-20),

3. 12344621 - CGRP antagonist compounds (2025-07-01),

4. 12227521 - CGRP antagonist compounds (2025-02-18),

5. 12178813 - CGRP receptor antagonists (2024-12-31),

6. 10888561 - CGRP receptor antagonists (2021-01-12),

7. 10300056 - CGRP receptor antagonists (2019-05-28),

8. 10259812 - CGRP receptor antagonists (2019-04-16),

9. 10166226 - CGRP receptor antagonists (2019-01-01),

10. 9925178 - CGRP receptor antagonists (2018-03-27),

11. 9808457 - CGRP receptor antagonists (2017-11-07),

12. 9802935 - CGRP receptor antagonists (2017-10-31),

13. 9688660 - CGRP receptor antagonists (2017-06-27),

Title: Francesca Deflorian: A Pioneer in CGRP Antagonist Innovations

Introduction

Francesca Deflorian is an accomplished inventor based in Cambridge, GB, renowned for her significant contributions in the field of pharmacology. With a remarkable portfolio of 11 patents, she has established herself as a pioneer in developing innovative compounds aimed at addressing disorders associated with CGRP receptors.

Latest Patents

Her recent patents focus on CGRP antagonist compounds, detailing novel compounds of Formula (1) and Formula (1a). These disclosures reveal salts thereof, with specific definitions for components A, Q, X, R, W, Z, L, and R involved in the treatment, prevention, amelioration, control, or reduction of risks related to disorders linked to CGRP receptors. Her innovative work is paving the way for new therapeutic options in this critical area.

Career Highlights

Throughout her career, Francesca has made notable advancements while working with prominent companies such as Heptares Therapeutics Limited and Nxera Pharma UK Limited. Her expertise in the drug development sector has propelled her work to the forefront of medical innovations.

Collaborations

Francesca has collaborated with esteemed colleagues, including Miles Stuart Congreve and John Andrew Christopher. Together, they have contributed to the advancement of drug research and development, showcasing the importance of teamwork in achieving groundbreaking innovations in the pharmaceutical industry.

Conclusion

Francesca Deflorian's dedication to her field is evident through her impressive patent portfolio and collaborative efforts in research. As she continues to innovate, her work will undoubtedly have a lasting impact on the medical community and beyond.

Profile summary based on public USPTO records.